Compare NICE Ltd (NICE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Recursion Pharmaceuticals Inc — how do they compare? NICE Ltd trades at $120.3 (market cap $6.81B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: NICE Ltd is far larger — about 3.2× Recursion Pharmaceuticals Inc's market cap, and NICE Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 15 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NICE | RXRX | |
|---|---|---|
Market Cap | $6.81B | $2.14B |
Volume | 382,395 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $137.68 | $6.79 |
52-Week Low | $83.15 | $2.84 |
Typical Hold Time | 15 Days | 22 Days |
Enterprise Value | $6.54B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE Ltd. (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 17.08 and strong profitability margins, including a 65.12% gross margin. Recent earnings have consistently beaten expectations, and analyst consensus is bullish with a $124.20 price target. Business developments include being named a leader in IDC MarketScape for contact center platforms, highlighting its competitive position in AI-driven customer experience solutions.
The outlook for NICE is positive, supported by AI-driven growth and a reasonable valuation. Investment opportunities include continued cloud and AI revenue expansion, while risks involve margin compression from heavy investment and market volatility. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
